Enter your keywords

Antidepressants – MO opportunities

Overview At the end of July 2023 NHSE published guidance titled “National medicines optimisation opportunities 2023/24”. This guidance describes the 16 national medicines optimisation opportunities for the NHS in 2023/24, and signposts to resources to help with their implementation. It recommends Integrated Care Boards (ICBs) choose at least five medicines optimisation opportunities to focus and […]

Sodium Valproate – MO opportunities

Overview At the end of July 2023 NHSE published guidance titled “National medicines optimisation opportunities 2023/24”. This guidance describes the 16 national medicines optimisation opportunities for the NHS in 2023/24, and signposts to resources to help with their implementation. It recommends Integrated Care Boards (ICBs) choose at least five medicines optimisation opportunities to focus and […]

Opioids – MO opportunities

Overview At the end of July 2023 NHSE published guidance titled “National medicines optimisation opportunities 2023/24”. This guidance describes the 16 national medicines optimisation opportunities for the NHS in 2023/24, and signposts to resources to help with their implementation. It recommends Integrated Care Boards (ICBs) choose at least five medicines optimisation opportunities to focus and […]

Social Prescribing: Evidence and Outcomes

Strategic Insight reports are designed to support strategic objectives and planning by Integrated Care System leaders. Through the analysis of data and communication with key stakeholders across the ICS, interventions to be undertaken by the ICS are proposed to Integrated Care Boards or associated committees. Social prescribing has been proposed as a mechanism to improve […]

NHS Medicines Optimisation Opportunities Dashboard 2023-24

At the end of July 2023 NHSE published guidance titled “National medicines optimisation opportunities 2023/24”. This guidance describes the 16 national medicines optimisation opportunities for the NHS in 2023/24, and signposts to resources to help with their implementation. It recommends Integrated Care Boards (ICBs) choose at least five medicines optimisation opportunities to focus and deliver […]

Drugs for Dementia

This report looks at prescribing trends in primary care for Drugs for Dementia at SICBL and ICB level with particular focus on low strength antipsychotics. Prescribing data is weighted with QOF registers. If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net Frequency Quarterly Data Period January 2021 to […]

Budget impact of paracetamol 250mg/5ml oral suspension

The purpose of this bulletin is to highlight the increase in cost of paracetamol 250mg/5ml oral suspensions since May 2022. It considers the potential savings that could be achieved through cost-effective paracetamol suspension prescribing across the ICSs in the North East & Yorkshire region and Greater Manchester.